OT

OS Therapies Incorporated

OSTX·NYSE

$1.42

-2.1%
HealthcareBiotechnology

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

At a Glance

Live Snapshot
Market Cap$50.00M
EPS-0.5200
P/E Ratio-2.73
Earnings Date03/30/2026

ostx

Other Current Assets

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

OT

OS Therapies Incorporated Competitors Analysis of Other Current Assets

OSTX · NYSE
CompanyOther Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
0.00
N/AN/AN/A
MNOV logo
MediciNova, Inc.
NASDAQ:MNOV
184.83K
1.8%N/AN/A
5.02M
-2.3%-18.2%N/A
2.40M
24.6%N/AN/A
54.69K
-43.5%N/AN/A
635.00K
-38.1%44.7%N/A
3.21M
17.7%51.9%N/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
4476.55B
8287.3%10567.9%N/A
OT

OS Therapies Incorporated Fair Value Envelope

OSTX · NYSE

Our analysis suggests that OSTX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.42, this represents a potential HIDDEN relative to our calculated worth for OS Therapies Incorporated.

Intrinsic Value
Current Price: $1.42